In addition, SNORD114‐17 is involved in several well‐known cancer‐related pathways, such as PI3K‐AKT signaling and the ECM receptor, suggesting that SNORD114‐17 may be an important regulator of the malignant phenotype. This evidence concerns the gene AKT1 and cancer.